Form 4: Director Fred E. Cohen Increases Stake in Kyverna

Director Fred E. Cohen acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics, Inc.

Summary

• Director Fred E. Cohen received an equity grant consisting of 5,093 restricted stock units (RSUs) and 20,582 stock options.
• The stock options have an exercise price of $8.59 per share.
• Both the RSUs and the stock options are scheduled to vest in full on May 27, 2027, or immediately prior to the 2027 annual meeting of stockholders.
• Following the transaction, the director holds 21,727 shares directly and maintains an indirect interest in 4,523,924 shares held by Vida Ventures, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership through a one-year vesting schedule.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Dependence on the reporting person's continuous service to the issuer to achieve full vesting of the granted equity.

Future Outlook

The equity grants are subject to continuous service requirements through May 2027, indicating a commitment to the company's operational timeline over the next year.

Management Comments

• The transaction represents standard director compensation and alignment of interests.

Industry Context

StockSavvy.ai notes that equity grants to directors in the biotechnology sector are standard practice to ensure board members remain incentivized during critical clinical development phases.

Comparison to Industry Standards

• The use of one-year cliff vesting for director equity is consistent with standard corporate governance practices for mid-cap biotech firms.
• The inclusion of both RSUs and options is a common balanced approach to director compensation.

Related Party Transactions

• The director is a managing member of Vida Ventures Advisors, LLC, which serves as the investment advisor to Vida Ventures, LLC, a significant shareholder.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity grants on May 27, 2027.

Key Dates

Keywords

Kyverna Therapeutics, KYTX, Insider Trading, Form 4, Equity Compensation, Biotech